Skip to textbook content
Doctor’s PassportTextbook
QuestionsFlashcardsBriefsDashboardAccount
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Expectant, medical and surgical ectopic management

Obstetrics and gynaecology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Instability bypasses conservative options

Haemodynamic compromise, peritonism, rupture, significant pain or clinical deterioration requires urgent surgery and resuscitation; neither methotrexate nor expectant follow-up provides haemorrhage control.

Action: Call senior gynaecology, anaesthetics and theatre, initiate ABCDE and blood-component support, and proceed to operative management without delaying for serial hCG or completion of medical eligibility tests.

Synopsis

Select ectopic pregnancy treatment from stability, pain, ultrasound, hCG, follow-up and fertility factors, with exact thresholds and complete biochemical or postoperative follow-up.

  • Stability and pain come before hCG: rupture, haemodynamic compromise or significant pain requires surgery irrespective of biochemical concentration.
  • Offer expectant management when clinically stable and pain free, tubal ectopic is under 35 mm with no heartbeat, hCG is 1,000 IU/L or less and reliable follow-up is possible.
  • Consider expectant management at hCG above 1,000 but below 1,500 IU/L when every other criterion is met.
  • Offer systemic methotrexate when there is no significant pain, unruptured tubal ectopic under 35 mm with no heartbeat, hCG below 1,500 IU/L, no intrauterine pregnancy and reliable follow-up.
  • At hCG 1,500 to below 5,000 IU/L with no significant pain, mass under 35 mm, no heartbeat and no intrauterine pregnancy, offer a choice of methotrexate or surgery.
  • Offer surgery first for significant pain, mass at least 35 mm, visible fetal heartbeat, hCG at least 5,000 IU/L or inability to return for methotrexate follow-up.
  • After methotrexate, measure hCG on days 4 and 7 and weekly until negative; after expectant care use days 2, 4 and 7, then weekly when each fall is at least 15%.
  • At surgery, offer salpingectomy unless infertility risk such as contralateral tubal damage favours salpingotomy; the latter requires hCG follow-up and up to one in five need additional treatment.

Key red flags

New severe pain, shoulder-tip pain, dizziness, collapse, hypotension or guarding during expectant or methotrexate care may indicate rupture and needs immediate emergency assessment.

An adnexal mass at least 35 mm, visible fetal heartbeat, hCG at least 5,000 IU/L or significant pain makes surgery NICE first-line in tubal ectopic pregnancy.

Failure or inability to return for repeated hCG and emergency care makes outpatient expectant or methotrexate treatment unsafe.

Plateauing or rising hCG after treatment indicates persistent trophoblast and requires urgent review for repeat methotrexate or surgery before rupture occurs.

Investigation priorities

01
Expert transvaginal ultrasoundFirst step

Confirm site, mass size, fetal cardiac activity and free fluid before selecting conservative treatment.

Management branches

First-line emergency surgeryControl rupture and haemorrhage

The patient is unstable, has rupture, peritonism or significant pain and bleeding.

  1. Resuscitate with senior gynaecology, anaesthetic, theatre and transfusion teams and proceed without waiting for outpatient eligibility tests.
  2. Perform laparoscopy when feasible or laparotomy when rapid access, instability or complexity requires it, controlling haemorrhage and removing ectopic tissue.
  3. Provide postoperative monitoring, histology, current anti-D assessment, pregnancy-test or hCG follow-up and clear fertility and bereavement support.
Expectant first optionMonitor low-risk spontaneous resolution

The patient is stable and pain free with mass under 35 mm, no heartbeat, hCG at or below 1,000 IU/L and reliable follow-up.

  1. Explain alternatives, rupture symptoms and the need for immediate access, and confirm the patient accepts repeated blood tests and uncertainty.
  2. Measure hCG on days 2, 4 and 7; if each falls at least 15%, continue weekly until below 20 IU/L.
  3. Obtain senior review for a lesser fall, plateau, rise or symptom change and move promptly to methotrexate or surgery where indicated.

Key medicines

Methotrexate for tubal ectopic pregnancyAdminister a single intramuscular dose of 50 mg/m² under the specialist ectopic protocol after definitive diagnosis and baseline assessment; repeat treatment is determined by day 4 and day 7 hCG response.Do not use with rupture, significant pain, viable intrauterine pregnancy, breastfeeding, immunodeficiency, cytopenia, active lung disease, peptic ulcer, important liver or renal dysfunction or unreliable follow-up; avoid pregnancy for three months.
Open full textbook →Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG126 ectopic managementExact expectant, methotrexate, surgery and follow-up thresholds.
  • RCOG ectopic pregnancy informationTreatment outcomes, surgery, fertility and support.
  • NICE NG126 anti-D prophylaxisJune 2026 gestation-specific anti-D recommendations.
  • NHS ectopic pregnancy treatmentPatient-facing expectant, medical and surgical treatment.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom